A novel variant in MFN2 linked to a lethal disorder of neonatal onset

Authors: Mashiat Zaman[1], Julien L Marcadier[2], Amanda V Tyndall[3], Brenda McInnes[2], A Micheil Innes[4],

Francois P Bernier[4], Timothy E. Shutt[5]

[1]Department of Biochemistry & Molecular Biology, Cumming School of Medicine, Hotchkiss Brain

Institute, Alberta Children's Hospital Research Institute, University of Calgary

[2]Department of Medical Genetics, Cumming School of Medicine, University of Calgary

[3]Department of Medical Genetics, Cumming School of Medicine, Alberta Children's Hospital Research

Institute, Hotchkiss Brain Institute, University of Calgary

[4]Departments of Medical Genetics and Pediatrics, Cumming School of Medicine, Alberta Children's

Hospital Research Institute, University of Calgary

[5]Departments of Medical Genetics and Biochemistry & Molecular Biology, Cumming School of Medicine,

Hotchkiss Brain Institute, Snyder Institute for Chronic Diseases, Alberta Children's Hospital Research

Institute, University of Calgary

Abstract:

Pathogenic variants in the mitochondrial fusion protein Mitofusin2 typically cause axonal Charcot-Marie-

Tooth disease type 2A (CMT2A), a progressively degenerative peripheral neuropathy. Here, we present

two siblings with a lethal disorder of neonatal onset who carried a novel homozygous MFN2 variant

R334K. Given the severe clinical presentation, which is atypical of MFN2 variants, further functional

investigations were warranted to confirm the pathogenicity of the R334K variant, which was deemed to

be likely pathogenic. Characterization of patient fibroblasts showed severe disruptions all MFN2-related

functions that were assayed, including reduced mitochondrial respiration, altered mito-ER contacts,

decreased mtDNA copy number and size, as well as increased abundance of cellular lipid droplets. We

also observed reduced Complex I activity, which is noted in cells lacking MFN2, but is not standard for

pathogenic MFN2 variants that cause CMT2A. These functional deficits, combined with the fact that loss

of MFN2 is lethal in model organisms (e.g. mice/fruit-flies), support the notion that the MFN2 R334K is a

loss of function variant that is responsible for patient phenotype. Thus, we present a novel pathogenic

MFN2 variant causing severe fatal neonatal disease.

Synopsis Statement:

This work identifies a novel homozygous MFN2 variant, R334K, in two individuals with neonatal onset of

fatal disease.

Introduction:

Pathogenic variants in *MFN2* cause the hereditary motor sensory neuropathy Charcot-Marie-Tooth disease 2a (CMT2a), which is characterized by progressively worsening pain, numbness and weakness in the distal regions of the body. CMT2a is generally seen as an early-onset disease, with symptoms typically appearing around the age of 10. While CMT2a is most often autosomal dominant (CMT2A2A), there are cases of homozygous or compound heterozygous recessive inheritance (CMT2A2B) [1,2]. *MFN2* encodes the integral outer mitochondrial membrane (OMM) protein Mitofusin2 (MFN2), initially characterized for a role in mitochondrial fusion [3]. The protein consists of distinct domains, with an N-terminal GTPase domain, followed by two coiled-coiled heptad repeat (HR) domains separated by a transmembrane domain.

The clinical presentation of CMT2a can vary widely, where some MFN2 variants are associated with additional patient pathology [4–6]. While there is evidence of specific MFN2 variants leading to severe and early pathology, neonatal lethality is exceedingly rare and there is one report of antenatal onset [7–10]. Though the reasons for this heterogeneity are unknown, it is notable that MFN2 has several other functions, including mediating mito-ER contacts (MERCs) [11], facilitating mito-lipid droplet contacts [12], participating in mitochondrial transport [13] and being a key regulator of mitophagy [14]. These MFN2 functions also influence downstream processes such as mtDNA regulation [15], cellular Ca^{2+} signalling [16] and mitochondrial bioenergetics [17]. The impact of different MFN2 variants on the various functions of MFN2 is largely unknown [17]. Surprisingly, for the few variants that have been studied fusion is not always impacted, suggesting that other MFN2 functions are also important in the context of pathology.

In this work, we describe two siblings who presented with areflexia, hypotonia and restricted movement upon birth, and who harbored a novel homozygous variant of unknown significance in MFN2, c.1001G>A, p.(Arg334Lys), which was deemed worthy of further investigation. We report detailed patient pathology and provide a comprehensive fibroblast characterization of mitochondrial functions associated with MFN2 that may contribute to the clinical outcomes.

Methods

Genomic analysis

The proband was enrolled into a research study titled Rapid Access for Pediatric Diagnoses Kidomics (RAPiD) at the Alberta Children's Hospital. Formal written consent was provided by the family (mother, father, and proband) for both the RAPiD research exome (study approved by the University of Calgary Conjoint Health Research Ethics Board) sequencing and the clinical whole exome sequencing. DNA was extracted from whole blood samples, and trio exome library preparation was conducted using the xGen Exome Research Panel v1.0 capture kit (Integrated DNA Technologies, Inc., Coralville, IA, USA). Paired-end sequencing was performed on a NextSeq 550 (Illumina, San Diego, CA, USA) in which data was automatically uploaded into BaseSpace Sequencing Hub where alignment, variant calling, and variant interpretation was completed.

Sequence alignment

Amino acid sequence alignment was performed on T-COFFEE multiple sequence alignment tool [18]. Protein sequences were collected from the UniProt database [19]. Human MFN2: O95140-1; Human MFN1: Q8IWA4; Mouse MFN2: Q80U63; Fish MFN2: A8WIN6; Fly MFN2: Q7YU24; Worm MFN2: Q23424; FXRD1: Q96CU9; FXRD1 [2]: Q96CU9-2 ; FXRD1 [3]: Q96CU9-3; Mouse FXRD1: Q3TQB2; Fish FXRD1: A0A0R4IHD6; Fly FXRD1: Q9VJ10; Worm FXRD1: A0A0V1BI76 .

Cell culture

Skin fibroblasts were cultured in Minimum Essential Media (Gibco™, 11095098), supplemented with 10% Fetal Bovine Serum (FBS) and 10mM Sodium Pyruvate. The cells were maintained at 37°C and 5% CO_2.

Respiration studies

Cellular oxygen consumption rates were measured using the Seahorse XFe24 Extracellular Flux Analyzer (Agilent Technologies) as previously described [20]. In summary, cells were seeded in the manufacturer provided microplate at 70,000 cells/well and incubated for 24 hours at 37°C and 5% CO_2. Subsequently, the growth media was replaced, and cells equilibrated in assay media supplemented with d-Glucose (25 mM), sodium pyruvate (2 mM) and l-Glutamine (4 mM). Oxygen consumption rates were

86 calculated following administration of the following compounds: Oligomycin (1 µg/mL) (Enzo Life

87 Sciences, BML-CM111), Carbonyl Cyanide 4-(trifluoromethoxy) Phenylhydrazone (FCCP, 1 µM) (Enzo life

88 Sciences, BML-CM120) and Antimycin A (1 µM) (Sigma Aldrich, A8674). The data from the Seahorse

89 analyzer was normalized to protein content data for each well measured by BCA assay (Thermo Fisher

90 Scientific, 23225).

Immunofluorescence and Microscopy

Control and patient fibroblasts were seeded on coverslips (Fisherbrand, 12-545-81) at a density

of 20,000 cells and incubated for 24 hours at at 37°C and 5% CO_2. Cells were fixed with 4%

paraformaldehyde at 37°C for 20 minutes, permeabilized using 0.1% Triton® X-100 (MP Biomedicals,

9002-93-1) and blocked with 10% FBS. The mitochondrial network was stained with anti-TOMM20

(Sigma-Aldrich, HPA011562/Santa Cruz Biotechnology, F-10 sc-17764) primary antibodies and visualized

using goat anti-rabbit secondary conjugated with Alexa Fluor 488 (ThermoFisher, A-11034) or goat anti-

mouse conjugated Alexa Fluor (ThermoFisher, A-31571). Mitochondrial nucleoids were visualized using

anti-dsDNA antibody (Developmental Studies Hybridoma Bank, AB_10805293) and goat anti-mouse

secondary conjugated with Alexa fluor 568 (ThermoFisher, A-11004), following permeabilization with

0.2% Triton® X-100**.** Lipid droplets were tagged using anti-PLIN1 antibody (Cell Signalling Technology,

9349S). Confocal imaging was performed using Olympus spinning disc confocal system (Olympus SD

OSR) (UAPON 100XOTIRF/1.49 oil objective). STED imaging was performed using Leica TauSTED

microscope. The mitochondrial network was analyzed using the MiNA plugin on FIJI [21]**.**

Proximity Ligation Assay:

The proximity ligation assay was performed as mentioned in [6]. All immunostaining steps,

including fixation, blocking and permeabilizing were the same as mentioned above. The Duolink® In Situ

Proximity Ligation Assay (Millipore Sigma) was used for this. The aforementioned TOMM20 was used to

label the mitochondria and the ER was labelled using anti-Calnexin (mouse monoclonal, EMD Millipore:

MAB3126 (RRID:AB_2069152). Images were analyzed using confocal microscopy (as described above)

and PLA puncta were analyzed using the 'analyze particles' tool on FIJI.

Western Blot Analysis

Cells at the same confluency were collected and RIPA buffer (Thermo Scientific™, 89900)

complimented with protease inhibitors was used to lyse and collect the protein extracts. Following

quantification of protein concentrations, 50 µg of total protein from control and patient fibroblasts were

loaded on an SDS-PAGE gel. Subsequently, PVDF membranes were used for overnight transfer of the

blots. The blots were probed with the following antibodies: anti-MFN2 (Abnova, H00009927-M03;

1:1000), anti-MFN1 (Cell Signaling Technology, D6E2S; 1:1000), anti-OPA1 (BD Transduction

Laboratories, 612607; 1:1000), anti-Actin (Sigma, A5316; 1:1000) and cocktail anti-OXPHOS Complex

antibody (AbCam, ab110411). Complimentary horseradish peroxidase conjugated antibodies were used:

goat anti rabbit IgG, HRP linked Antibody (Cell Signaling Technology, 7074S) or goat anti-mouse IgG-HRP

(Santa Cruz Biotechnology, sc-2055). Blots were treated with the SuperSignal™ West Femto Maximum

Sensitivity Substrate (Thermo Scientific™, 34095), and luminescence visualized with an Amersham

Imager AI600.

mtDNA Copy Number and mtDNA Deletions Analysis

Total DNA was extracted and purified from control and patient fibroblasts seeded at 30,000 cells

using the PureLink Genomic DNA Mini Kit (Thermo Fisher Scientific, K182001) using the given protocol.

Relative mtDNA copy number was analysed using QuantStudio 6 Flex Real-Time PCR system (Thermo

Fisher Scientific). The mtDNA and nuclear encoded housekeeping gene 18S were amplified using the

primers and reaction conditions described in [22]. Long range PCR reactions were performed to examine

mtDNA deletions. The following primers were used for amplification of the mtDNA: 1482–1516 F:

ACCGCCCGTCACCCTCCTCAAGTATACTTCAAAGG; 1180–1146 R:

ACCGCCAGGTCCTTTGAGTTTTAAGCTGTGGCTCG. The Takara LA Taq Polymerase (Takara Bio, RR002M)

was used with 250ng total cellular DNA. PCR cycling conditions were 94°C for 1 min; 98°C for 10 s and

68°C for 11 min (step 2 and 3- 35 cycles); and a final extension cycle at 72°C for 10 min, using an

Eppendorf® 5331 MasterCycler Gradient Thermal Cycler. PCR products were visualized by

electrophoresis on a 0·6% agarose gel, run for approximately 18 h at 20 V.

Complex-I Activity Assay

The mitochondrial complex-I activity assay was performed using the Complex I Enzyme Activity

Dipstick Assay Kit (AbCam, ab109720) according to manufacturer instructions. Briefly, 50,000 cells were

seeded and collected the following day. 10x Extraction buffer from the kit was added to the cell pellet

and subsequently spun at 18,000 x g. Supernatants were collected and following homogenization,

control and patient samples were plated in the plate provided. Subsequently, the dipstick from the plate

was added and incubated for 45 minutes. Following washing procedures, the dipsticks were imaged with

Amersham Imager AI600.

Statistical Analyses

All statistical analyses were performed using GraphPad Prism 9.

Results:

Case description:

Proband (P1)

The male proband was born by C-section for preterm labor, breech presentation and fetal heart

rate abnormalities to a 21-25-year-old G3, P0 mother. The pregnancy was remarkable only for a mild

COVID infection in the first trimester with three antenatal ultrasounds reported as completely normal.

Decreased fetal movements were noted in the last 4 to 8 weeks of the pregnancy. His birthweight was in

the 10th percentile, length was in the 50th percentile, and head circumference was in the 50th

percentile. APGARs were 1,3,3,6 at 1, 5,10 and 15 minutes respectively. He remained flat with no

respiratory effort and was intubated at 6 minutes of life. He remained ventilator dependent and

eventually died in the pediatric intensive care unit at 2-6 weeks of age. On examination he was noted to

have hypotonia both peripherally and axially with decreased spontaneous movements. He had bilateral

flexion contractures at his elbows and knees with limited hip abduction and talipes equinovalgus. He

was noted to have a bulbous nasal tip but a complete dysmorphology exam was not feasible.

Investigations included normal newborn metabolic screening, normal rapid aneuploidy

detection, SNP chromosomal microarray, Prader Willi, DM-1 and SMA. While chromosomal microarray

analysis did not reveal any copy number variation to explain the proband's phenotype, the SNP

component of the analysis revealed three contiguous regions (greater than 10Mb) of absence of

heterozygosity (AOH) within chromosomes 1, 3, and 4. Metabolic investigations revealed normal urine

and plasma amino acids and a normal plasma acylcarnitine profile. Urine organic acids were non

diagnostic and plasma 3-methylglutaconic acid and 3-methylglutaric acid were also normal. EEG was

indicative of moderate diffuse/multifocal cerebral dysfunction with multifocal epileptiform discharges.

Brain MRI shortly after birth showed multiple foci of diffusion restriction due to cytotoxic edema

involving the deep and periventricular white matter in frontoparietal lobes with corresponding intrinsic

T1 hyperintensity. There were no overt signs on imaging or MRS to suggest a metabolic cause. A follow-

up brain MRI just prior to death reported interval resolution of the multiple foci of restricted diffusion in

the bilateral centrum semiovale ovale/corona radiata, with a few small scattered residual centrum

semiovale T1 hyperintense foci without restricted diffusion. As compared to the previous MRI, there was

interval development of atrophy of the superior vermis, seen as increased interfoliate distance. Mild

atrophy was also seen involving the lateral cerebellar hemispheres. The brain stem structures, especially

the midbrain and pons, had reduced volume for patient's age, with prominence of the prepontine

cisterns, resulting in prominence of the posterior fossa CSF spaces without mass effect. The remainder

of the midline structures appeared normal with no Chiari I deformity and a normal pituitary gland. The

corpus callosum was well developed and the remaining brain parenchyma was normal with an age-

appropriate myelination pattern. No new areas of restricted diffusion or abnormal signal involving the

cerebrum or cerebellum were observed and there was no abnormal susceptibility-related signal loss to

suggest blood degradation products. The brain stem structures, especially the midbrain and pons had

reduced volume for the patient's age. Additional imaging of the patient's spine showed marked smooth

hypoplasia and reduced caliber of the thoracic spinal cord. In addition, the brainstem and thoracic spinal

cord reported to be small.

A muscle biopsy was performed shortly before death revealing no definite abnormalities but

coarse NADH, SDH, and COX histochemistries were observed in addition to mild mitochondrial

aggregation in the subarcolemmal spaces with some smaller mitochondria but normal cristae. There

were grouped atrophic fibres and occasional hypertrophic fibres.

Proband's sibling (P2)

The proband's male sibling presented with the same core phenotype of encephalopathy,

hypotonia, hyporeflexia, arthrogryposis. The sibling had an unremarkable prenatal history with normal

initial anatomy scan. A second prenatal scan revealed breech presentation but otherwise normal with

normal fetal movements. A further scan was appropriate for gestational age and showed breech

presentation. He was born via C-section due to preterm labor with APGARS 1, 2, and 3 at 1, 5 and 10

minutes respectively, with no spontaneous respirations. He was intubated and admitted to NICU. He

required continuous mandatory ventilation. Life sustaining measures were withdrawn between day 11-

15 and the patient died the same day. An autopsy was declined.

On examination at birth, the baby was noted to be hypotonic with contractures and decreased

range of motion of elbows, hips and knees with bilateral talipes equinovarus. His birth weight was in the

50th percentile, length was in the 90th percentile, and head circumference was in the 50th percentile. He

had depressed/absent reflexes. Investigations included a normal newborn metabolic screen, normal

lactates, ammonia, and liver enzymes with a mildly elevated CK. An EEG was consistent with

encephalopathy. Brain MRI showed cerebellar hypoplasia with query germiolytic cysts. An MRI of the

spine was normal.

Genetic workup:

Upon initial research RAPID exome sequencing, trio analysis of P1 and parents, who were

distantly consanguineous, detected the homozygous c.1001G>A, p.(Arg334Lys) variant of uncertain

significance in the MFN2 gene. Pathogenic variants in MFN2 are associated with autosomal dominant

and autosomal recessive Charcot-Marie-Tooth disease, axonal, type 2A. While patients with variants in

MFN2 have a heterogeneous clinical presentation with an age of onset ranging from 1-45 years,

previously reported individuals with homozygous or compound heterozygous variants presented before

the age of 10 years [23,24]. These affected individuals presented with muscle weakness, distal sensory loss,

and normal or mildly decreased nerve conduction velocity, while the heterozygous parents were

reported to be asymptomatic or had signs of a mild peripheral neuropathy [24]. This variant has not been

reported in gnomAD, ClinVar, or the literature. This missense variant resides near the middle of exon 10

of 19 and appears to abolish a potential cryptic donor splice site within this exon. The consequence of

the loss of this cryptic donor splice site is unknown. A subsequent clinical exome of P1 confirmed the

homozygous MFN2 c.1001G>A, p.(Arg334Lys) variant, and also found a novel homozygous missense

variant of unknown significance, c.1454T>A, p.(Ile485Asn), in FOXRED1, a gene associated with complex

I deficiency [25–28].

Sanger sequencing was used to assess the genetic status of P2. Analysis found homozygosity for

MFN2 Arg334Lys, but only heterozygosity for FOXRED1 Ile485Asn. The family also had an unaffected

sister, for whom no genetic information was obtained.

Based on the genetic work-up from P1, we initially considered both MFN2 R334K and FOXRED1

I485N variants. Given that the candidate variants in MFN2 and FOXRED1 have not been described or

characterized previously, we examined the conservation of the corresponding amino acid changes in the

protein. We found that the MFN2 R334 residue is conserved in multiple species, including fruit flies and

worms, as well as in the paralogous protein MFN1, arguing that it plays an important role in protein

function (Figure 1A). Meanwhile, though the FOXRED1 I485 residue is conserved in vertebrates, it is not

conserved in earlier diverging metazoans such as flies or worms (Figure 1B). Upon subsequent

sequencing of P2, who was homozygous for MFN2 R334K, but only heterozygous for and FOXRED1

I485N, it became evident that MFN2 R334K was most likely the causative variant for the remarkably

consistent phenotype in the two brothers.

Characterization of patient fibroblasts harboring MFN2 R334K:

As the candidate pathogenic variant in MFN2 is novel and has not been characterized previously,

fibroblasts from a skin biopsy of P1, who harboured homozygous MFN2 R334K and FOXRED1 I485N

variants, were obtained for functional analysis. We examined a variety of cellular and mitochondrial

phenotypes to see which, if any, might be consistent with MFN2 and/or FOXRED1 dysfunction.

Unfortunately, fibroblast cells were not available for P2.

Patient fibroblasts show evidence of mitochondrial dysfunction:

Given the integral role of mitochondria in ATP production, we first assessed oxygen

consumption in patient fibroblasts, as this is a key indicator of changes to mitochondrial function.

Compared to control cells, we observed marked decreases in both basal and maximal oxygen

consumption (Figure 2A), as well as spare respiratory capacity (Fig 2B). These findings are indicative of

reduced mitochondrial respiration in patient fibroblasts, consistent with an underlying mitochondrial

dysfunction contributing to the patient phenotype.

Next, we investigated the canonical function of MFN2 in mitochondrial fusion by visualizing the

mitochondrial network after immunofluorescent labeling for the mitochondrial marker TOMM20 (Figure

2C). In comparison to the control fibroblasts, which showed elongated and reticular mitochondrial

network morphology, patient fibroblasts qualitatively displayed more fragmented mitochondrial

networks (Figure 2D). Quantitative analysis of the mitochondrial networks confirmed patient fibroblasts

had shorter mitochondria (Figure 2E). Together, these findings are consistent with impaired

mitochondrial fusion leading to more fragmented mitochondria.

Changes in mitochondrial nucleoids and mtDNA copy number depletion in patient fibroblasts:

To provide further evidence of impaired mitochondrial fusion, we investigated the distribution

and abundance of mtDNA, which can be altered by impairments to mitochondrial fusion, are linked to

loss of MFN2 function, and have been observed for some MFN2 variants [17,29,30]. Immunofluorescence

imaging of mtDNA nucleoids (Figure 3A) revealed that the patient fibroblasts exhibited approximately

half as many nucleoids as control fibroblasts (Figure 3B), and that patient mtDNA nucleoids were smaller

(Figure 3C). Consistent with the reduced number of mtDNA nucleoids, we detected a 40% decrease in

the mtDNA copy number in the patient fibroblasts via qPCR (Figure 3D). Finally, we also investigated the

presence of mtDNA deletions, which are sometimes seen with MFN2 loss of function [17]. However, no

mtDNA deletions were detected (Figure 3E).

Altered mito-ER contact sites and lipid droplet accumulation in patient fibroblasts:

We investigated the size and abundance of mito-ER contact sites (MERCs) and lipid droplets, as

these phenotypes can be altered in fibroblasts from patient harboring pathogenic MFN2 variants [6,31]. As

a proxy for MERCs, we utilized a proximity ligation assay (PLA) that generates a fluorescent signal when

mitochondria and ER are within ~40 nm (Figure 4A,4B) [32]. Using confocal microscopy, we observed a

decrease in the size and number of MERCs, which was confirmed by quantitative analyses (Figure 4C,D).

We examined lipid droplets by immunofluorescence with the lipid droplet surface protein Perilipin 1

(Figure 5A). Compared to control fibroblasts, we noted a distinct upregulation in the number (Figure 5B)

and size (Figure 5C) of PLIN1 puncta in the R334K patient fibroblasts. These findings of decreased MERCs

and increased lipid droplets are consistent with previously reported alterations in fibroblasts from

patients with CMT2A harbouring MFN2 variants [12,31].

MFN2 and mitochondrial protein expression:

As our findings were consistent with MFN2 dysfunction, we assessed if expression of MFN2 and

other mitochondrial proteins was impacted. While we did not observe changes in MFN2 protein levels

from total cell lysate (Figure 6a-b), we did observe a significant (~50%) decrease in expression of the

nuclear DNA encoded mitochondrial complex I subunit NDUFB8 (Figure 6A,C). Notably, there was no

consistent significant change to the levels of the other OXPHOS proteins investigated here, including

mtDNA-encoded MTCO1. The cause for this discrepancy in OxPhos protein expression is unknown, but

likely does not reflect the mtDNA depletion, which would be expected to cause a global decrease in

OxPhos protein expression as mtDNA encodes essential proteins for all the electron transport chain

complexes except for complex II.

Complex I activity:

Given the specific decrease in a Complex I protein, which is not typical of MFN2 dysfunction and

likely not explained by mtDNA depletion, we wondered if the identified FOXRED1 missense variant

might also have functional consequences that could contribute to the patient phenotype. As pathogenic

defects in FOXRED1 are linked to dysfunction in complex I assembly and stability, we also examined

Complex I activity. Consistent with the reduced protein expression, and possible complex I instability, we

observed an ~50% reduction in Complex I activity in patient fibroblasts (Figure 6D,E).

Discussion:

We report two siblings who presented with severe hypotonia, areflexia and limited movement

upon birth, who both harboured a novel homozygous single missense variant in MFN2 p.(Arg334Lys).

Though CMT2A can be an early-onset disease that can eventually restrict patient movement as the

disease progresses, the patients reported here exhibited lack of movement upon birth, indicative of a

more severe disease onset. Moreover, both patients succumbed in infancy (<6 weeks). Though areflexia

and hypotonia phenotypes are not typical of CMT2A, there are a few previous reports of both these

phenotypes in patients harbouring MFN2 variants with severe early onset disease prognosis [23,30,33–36].

However, the patients we report here presented with symptoms immediately upon birth, as opposed to

the examples in the previous reports, where symptoms presented from 6-12 months. With respect to

the early onset of severe phenotypes linked to MFN2 dysfunction, there is a recent report of a patient

with severe CNS complications who harboured a homozygous 50 amino acid deletion in MFN2 with

antenatal presentation that resulted in pregnancy termination at 31 weeks [10]. In this regard, the fact

that loss of MFN2 function leads to embryonic lethality in mice [3] and larval lethality in fruit flies [37], is

consistent with a severe loss of MFN2 function due to the R334K variant.

In support of the notion that the R334K variant impairs MFN2 functions, we observed changes

across all the functions we explored, including mitochondrial network morphology, oxidative

phosphorylation, complex I activity, MERCs, mtDNA copy number and nucleoids, as well as cellular lipid

droplets. These findings suggest that the novel R334K variant causes severe dysfunction of the MFN2

protein. To our knowledge, there are no previously characterized MFN2 CMT2a variants with defects

across all these functions [17]. However, this finding likely reflects the fact that few MFN2 variants have

been characterized extensively for their impact on MFN2 functions, highlighting our limited

understanding of how MNF2 variants impact MFN2 functions. In terms of MFN2 variants associated with

more severe cellular phenotypes, it is notable that MFN2 variants that correlate with reduced mtDNA

copy number and impaired oxidative phosphorylation are reported in patients that tend to present with

earlier-onset and severe clinical outcomes [6,38,39]. Collectively, this evidence is consistent with severe

MFN2 dysfunction contributing to the very early onset of clinical symptoms in the patients we report

here.

It is also worth briefly discussing the Complex I deficiency in P1, which is not typical of

pathogenic MFN2 variants, especially in light of the additional homozygous FOXRED1 variant in this

patient. Notably, complete loss of MFN2 function can lead to a specific deficit in complex I expression

and function [40]. Moreover, Complex I dysfunction was also reported with the MFN2 variant harbouring a

50 amino acid deletion where the patient also presented immediately upon birth with a severe

phenotype [10]. Thus, MFN2 dysfunction alone is sufficient to cause Complex I deficiency.

Though FOXRED1 is a molecular chaperone that is important for the assembly of mitochondrial

complex I [25,41], several lines of evidence argue against a potential role for the I485N variant contributing

to the phenotype of the patients. First, the patient phenotypes do not match. Homozygous or

compound heterozygous recessive FOXRED1 variants cause mitochondrial complex I deficiency, nuclear

type 19 (MC1DN19), where only a handful of cases have been described [25,26,28,42–45]. Clinical phenotypes

of MC1DN19 mimic common mitochondrial disorders such as Leigh syndrome and mitochondrial

encephalopathy [42,43,46], including lactic acidosis and growth restrictions. In contrast, there was no

evidence of lactic acidosis in P1 or P2. Meanwhile, though MC1DN19 patients can have hypotonia [28,42],

and can also be diagnosed with restricted movement accompanying Leigh syndrome [25], there are no

reports of areflexia in FOXRED1 patients, who typically survive well past infancy [26]. Secondly, the

genetics also argue against I485N FOXRED1 variant contributing to pathology, as FOXRED1 is autosomal

recessive, while P2 was heterozygous for the I485N FOXRED1 variant. Thus, despite the fact that novel

I485N FOXRED1 variant reported here is located at the C-terminus of the protein, similar to other

pathogenic FOXRED1 variants described to date, and the fact that FOXRED1 patient fibroblasts also have

reduced Complex I activity [28] (with patient myoblasts reported with deficiencies in both Complex I and

Complex II [44]), this variant was ruled out as a contributing factor for the phenotype of P1 and P2, who

had identical presentations. Of note, it is also possible that the FOXRED variant may have contributed to

a milder phenotype that was masked by the more severe MFN2 disorder.

Rapid whole exome sequencing (WES) has repeatedly shown that a quicker time to diagnosis

guides goals of clinical care, including less failed treatments, and ultimately lowers the financial burden

on the health care system [47–49]. While previous reports suggests that between 30-50% of WES cases are

solved or partly solved by a known disease-associated gene, additional cases may reveal novel genes of

uncertain significance (GUS). This study demonstrates the utility of rapid WES accompanied by

functional experiments to assess these GUS and provide a diagnosis. Functional studies also have the

potential to discover new treatment options for novel genes. However, as this study demonstrates, this

is dependent upon the damaging effects of the variant on the normal function of the gene and/or

protein. Regardless, this study demonstrates the value of collaboration between clinical and research

colleagues.

To summarize our findings, we report severe clinical symptoms upon birth in two siblings

homozygous for the novel MFN2 R334K variant, and observed numerous cellular dysfunctions in patient

fibroblasts that can be explained by loss of MFN2 function. Thus, we speculate the location of the R334K

MFN2 variant is crucial for proper protein function, possibly by altering the nearby GTPase domain of

the protein. In summary, we suggest the novel MFN2 R334K variant significantly impairs the MFN2

protein and is causative of the severe patient phenotype.

Acknowledgements

The authors would like to thank the study participants and their family. We would also like to

thank Matthew Lines for his input on the manuscript.

369
370 **Conflict of Interests**

371   The authors declare that they have no conflict of interest.

372
373 **Author contributions**

374   Designed and/or performed and analyzed mitochondrial experiments, MZ and TES; Clinical

375 evaluation of patients and write up, JLM, BM, AMI, FPB; Analyzed exome data AVP; Drafted the

376 manuscript or figures, MZ, AVP, BM, TES. All authors discussed the results and commented on the

377 manuscript.

378
379 **Funding**

380   This work was supported by funds provided by the Canadian Institutes of Health Research (TES)

381 and the Alberta Children's Hospital Research Institute (Owerko Center) (MZ). MZ was supported by a

382 Hotchkiss Brain Institute International Recruitment Scholarship. The funders had no role in study design,

383 data collection and interpretation, or the decision to submit the work for publication.

 Figure Legends:

Figure 1: Importance (conservation) of amino acid variants in MFN2/FXRD1. Multiple sequence

alignment showing (A) MFN2 conservation of arginine-334 and (B) FOXRED1 conservation of isoleucine

485. Accession numbers: Human MFN2: O95140-1; Human MFN1: Q8IWA4; Mouse MFN2: Q80U63; Fish

MFN2: A8WIN6; Fly MFN2: Q7YU24; Worm MFN2: Q23424 ; FXRD1: Q96CU9; FXRD1 [2]: Q96CU9-2 ;

FXRD1 [3]: Q96CU9-3; Mouse FXRD1: Q3TQB2; Fish FXRD1: A0A0R4IHD6; Fly FXRD1: Q9VJ10; Worm

FXRD1: A0A0V1BI76 .

Figure 2: Mitochondrial dysfunction and network fragmentation in patient fibroblasts. Oxygen

Consumption Rate (OCR) for control and patient fibroblasts, showing the Seahorse Mitochondria Stress

Test profile (A) and quantification of spare respiratory capacity (B), using two biological replicates with

10 technical replicates each, bar graphs indicate mean +/- SD. (C) Representative super resolution (STED)

microscopy immunofluorescence images showing mitochondrial network morphology, stained using

anti-TOMM20. (D) Qualitative analysis of mitochondrial branch appearance

(fused/intermediate/fragmented) analyzed using two biological replicates with 50 cells for each, bar

graphs indicate mean for each category +/- SD. (E) Average mitochondrial branch lengths in control and

patient fibroblasts, analyzed from 2 biological replicates with 50 cells for each replicate. Violin plots

indicate median and interquartile range. For all graphs, p-values were determined by unpaired t-test (*

indicates $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, *** $p \leq 0.0001$).

Figure 3: MtDNA alterations in patient fibroblasts. (A) Representative confocal microscopy images

showing DAPI (nucleus; blue) and mitochondrial nucleoids (anti-dsDNA; red) co-localized with the

mitochondrial network (anti-TOMM20; teal) for control (top panels) and patient fibroblasts (bottom

panels). Quantitative analyses of average number of mitochondrial nucleoids per cell (B) and average

size (C) per cell in control and patient fibroblasts, analyzed from 2 biological replicates with 40 cells for

each category; red and blue colors indicate different biological replicates; lines indicate mean +/- SD. (D)

Quantitative analysis of control and patient fibroblast mtDNA copy number via quantitative PCR relative

to 18S rDNA, analyzed from 2 biological replicates indicated by red and blue colors, with 3 technical

replicates each, bar graphs indicate mean +/- SD. (E) Agarose gel image of long-range PCR products from

the amplification full-length mtDNA in control and patient cells shows no mtDNA deletions; ladder

shown on the left with indicated sizes. For all graphs, p-values were determined by unpaired t-test (*

indicates p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, ***p ≤ 0.0001).

Figure 4- Reduced size and numbers of mitochondrial-ER contact site in patient fibroblasts.

Representative confocal microscopy images for control (A) and patient (B) fibroblasts showing

mitochondria (anti-TOMM20; teal), ER (anti-calnexin; magenta), and MERCs (PLA probes; yellow)

channels alone and merged. The top panel shows an entire cell, while the bottom panel shows the

zoomed-in region indicated by the boxed region above. Quantitative analyses of the average MERC

puncta size (C) and number(D) per cell as analyzed from 2 biological replicates with 15 cells for each

condition. Violin plots show median and interquartile range. Bar graphs indicate mean and SD with

biological replicates indicated by red and blue colors. For all graphs, p-values were determined by

unpaired t-test (* indicates p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, ***p ≤ 0.0001).

Figure 5: Increased size and numbers of lipid droplets patient fibroblasts. (A) Representative confocal

images from control (top) and patient (bottom) fibroblasts stained for lipid droplets (anti-PLIN1; teal)

and mitochondria (anti-TOMM20; magenta), far right panel shows zoom inset of white box region.

Quantification of mean lipid droplet number (B) and size (C) per cell in control and patient fibroblasts

analyzed from 3 biological replicates indicated by red, yellow, blue colors, with 10 cells for each sample.

Bar graphs show mean +/- SD. Violin plots indicate media and quartile ranges, while lines show median

and +/- SD. For all graphs, p-values were determined by unpaired t-test (* indicates p ≤ 0.05, ** p ≤ 0.01,

*** p ≤ 0.001, ***p ≤ 0.0001).

Figure 6: Reduced Complex-I protein level and activity in patient fibroblasts. (A) Representative

western blot images from control and MFN2 R334K patient fibroblasts, showing protein levels of MFN2

and the indicate oxidative phosphorylation complex proteins, as well as a beta-Actin loading control and

HSP60 as a mitochondrial loading control. (B) Quantification of MFN2 protein levels in control fibroblasts

and patient fibroblasts relative to Beta-Actin; analyzed from two biological replicates (red and blue on

graph) with three technical replicates for each; bar graphs indicate mean +/- SD. (C) Quantification of

mitochondrial oxidative phosphorylation complex proteins (C-I: NDUFB8, C-II: SDHB, C-III: UQCRC2, C-IV:

COX II , C-V: ATP5A) from western blot analyses in control and patient fibroblasts normalized to cellular

beta-actin levels, analyzed from two biological replicates (red and blue on graph) with three technical

replicates for each, lines indicate mean +/- SD. (D) Images of Complex I activity from control and patient

fibroblasts, obtained using a complex-I dipstick assay, with quantification of relative complex-I activity

(E), analyzed from two biological replicates (blue and red on graph) with three technical replicates, bar

graphs indicate mean +/- SD. For all graphs, p-values were determined by unpaired t-test (* indicates p ≤

0.05, ** p ≤ 0.01, *** p ≤ 0.001, ***p ≤ 0.0001).

References:

1. Polke JM, Laurá M, Pareyson D, et al. Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations. *Neurology*. 2011;77(2):168-173. doi:10.1212/WNL.0b013e3182242d4d

2. Hikiami R, Yamashita H, Koita N, et al. Charcot-Marie-Tooth disease type 2A with an autosomal-recessive inheritance: the first report of an adult-onset disease. *J Hum Genet*. 2018;63(1):89-92. doi:10.1038/s10038-017-0353-3

3. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. *J Cell Biol*. 2003;160(2):189-200. doi:10.1083/jcb.200211046

4. Kimura Y, Nishikawa A, Hashiguchi A, et al. An MFN2-related Charcot-Marie-Tooth Disease Patient with Optic Nerve Atrophy, Neurogenic Bladder Dysfunction, and Diaphragmatic Weakness. *Intern Med*. 2022;61(11):1743-1747. doi:10.2169/internalmedicine.6487-20

5. Sawyer SL, Cheuk-Him Ng A, Innes AM, et al. Homozygous mutations in MFN2 cause multiple symmetric lipomatosis associated with neuropathy. *Hum Mol Genet*. 2015;24(18):5109-5114. doi:10.1093/hmg/ddv229

6. Sharma G, Zaman M, Sabouny R, et al. Characterization of a novel variant in the HR1 domain of MFN2 in a patient with ataxia, optic atrophy and sensorineural hearing loss. *F1000Res*. 2022;10:606. doi:10.12688/f1000research.53230.2

7. Bombelli F, Stojkovic T, Dubourg O, et al. Charcot-Marie-Tooth Disease Type 2A: From Typical to Rare Phenotypic and Genotypic Features. *JAMA Neurology*. 2014;71(8):1036-1042. doi:10.1001/jamaneurol.2014.629

8. Chung KW. Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. *Brain*. 2006;129(8):2103-2118. doi:10.1093/brain/awl174

9. Feely SME, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. *Neurology*. 2011;76(20):1690-1696. doi:10.1212/WNL.0b013e31821a441e

10.   Chevrollier A, Bonnard AA, Ruaud L, et al. Homozygous MFN2 variants causing severe antenatal
encephalopathy with clumped mitochondria. *Brain*. 2024;147(1):91-99. doi:10.1093/brain/awad347

11.   de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. *Nature*.
2008;456(7222):605-610. doi:10.1038/nature07534

12.   Boutant M, Kulkarni SS, Joffraud M, et al. Mfn2 is critical for brown adipose tissue thermogenic
function. *EMBO J*. 2017;36(11):1543-1558. doi:10.15252/embj.201694914

13.   Misko A, Jiang S, Wegorzewska I, Milbrandt J, Baloh RH. Mitofusin 2 is necessary for transport of
axonal mitochondria and interacts with the Miro/Milton complex. *J Neurosci*. 2010;30(12):4232-4240.
doi:10.1523/JNEUROSCI.6248-09.2010

14.   McLelland GL, Goiran T, Yi W, et al. Mfn2 ubiquitination by PINK1/parkin gates the p97-
dependent release of ER from mitochondria to drive mitophagy. Dikic I, ed. *eLife*. 2018;7:e32866.
doi:10.7554/eLife.32866

15.   Sidarala V, Zhu J, Levi-D'Ancona E, et al. Mitofusin 1 and 2 regulation of mitochondrial DNA
content is a critical determinant of glucose homeostasis. *Nat Commun*. 2022;13(1):2340.
doi:10.1038/s41467-022-29945-7

16.   Ainbinder A, Boncompagni S, Protasi F, Dirksen RT. Role of Mitofusin-2 in mitochondrial
localization and calcium uptake in skeletal muscle. *Cell Calcium*. 2015;57(1):14-24.
doi:10.1016/j.ceca.2014.11.002

17.   Zaman M, Shutt TE. The Role of Impaired Mitochondrial Dynamics in MFN2-Mediated Pathology.
Front Cell Dev Biol. 2022;10:858286. doi:10.3389/fcell.2022.858286

18.   Di Tommaso P, Moretti S, Xenarios I, et al. T-Coffee: a web server for the multiple sequence
alignment of protein and RNA sequences using structural information and homology extension.
Nucleic Acids Res. 2011;39(Web Server issue):W13-17. doi:10.1093/nar/gkr245

19.   UniProt Consortium. UniProt: the Universal Protein Knowledgebase in 2023. *Nucleic Acids Res*.
2023;51(D1):D523-D531. doi:10.1093/nar/gkac1052

20.   Sabouny R, Wong R, Lee-Glover L, et al. Characterization of the C584R variant in the mtDNA

depletion syndrome gene FBXL4, reveals a novel role for FBXL4 as a regulator of mitochondrial fusion.

Biochim Biophys Acta Mol Basis Dis. 2019;1865(11):165536. doi:10.1016/j.bbadis.2019.165536

21.   Valente AJ, Maddalena LA, Robb EL, Moradi F, Stuart JA. A simple ImageJ macro tool for

analyzing mitochondrial network morphology in mammalian cell culture. *Acta Histochem*.

2017;119(3):315-326. doi:10.1016/j.acthis.2017.03.001

22.   Eaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS. Ataxia-telangiectasia mutated kinase

regulates ribonucleotide reductase and mitochondrial homeostasis. *J Clin Invest*. 2007;117(9):2723-

2734. doi:10.1172/JCI31604

23.   Tan CA, Rabideau M, Blevins A, et al. Autosomal recessive MFN2-related Charcot-Marie-Tooth

disease with diaphragmatic weakness: Case report and literature review. *Am J Med Genet A*.

2016;170(6):1580-1584. doi:10.1002/ajmg.a.37611

24.   Nicholson GA, Magdelaine C, Zhu D, et al. Severe early-onset axonal neuropathy with

homozygous and compound heterozygous MFN2 mutations. *Neurology*. 2008;70(19):1678-1681.

doi:10.1212/01.wnl.0000311275.89032.22

25.   Formosa LE, Mimaki M, Frazier AE, et al. Characterization of mitochondrial FOXRED1 in the

assembly of respiratory chain complex I. *Hum Mol Genet*. 2015;24(10):2952-2965.

doi:10.1093/hmg/ddv058

26.   Apatean D, Rakic B, Brunel-Guitton C, et al. Congenital lactic acidosis, cerebral cysts and

pulmonary hypertension in an infant with FOXRED1 related complex I deficiency. *Mol Genet Metab*

Rep. 2019;18:32-38. doi:10.1016/j.ymgmr.2018.12.006

27.   Lemire BD. Evolution of FOXRED1, an FAD-dependent oxidoreductase necessary for

NADH:ubiquinone oxidoreductase (Complex I) assembly. *Biochim Biophys Acta*. 2015;1847(4-5):451-

457. doi:10.1016/j.bbabio.2015.01.014

28.   Fassone E, Duncan AJ, Taanman JW, et al. FOXRED1, encoding an FAD-dependent

oxidoreductase complex-I-specific molecular chaperone, is mutated in infantile-onset mitochondrial

encephalopathy. *Hum Mol Genet*. 2010;19(24):4837-4847. doi:10.1093/hmg/ddq414

29.   Silva Ramos E, Motori E, Brüser C, et al. Mitochondrial fusion is required for regulation of
mitochondrial DNA replication. *PLoS Genet*. 2019;15(6):e1008085. doi:10.1371/journal.pgen.1008085

30.   Renaldo F, Amati-Bonneau P, Slama A, et al. MFN2, a new gene responsible for mitochondrial
DNA depletion. *Brain*. 2012;135(Pt 8):e223, 1-4; author reply e224, 1-3. doi:10.1093/brain/aws111

31.   Larrea D, Pera M, Gonnelli A, et al. MFN2 mutations in Charcot-Marie-Tooth disease alter
mitochondria-associated ER membrane function but do not impair bioenergetics. *Hum Mol Genet*.
2019;28(11):1782-1800. doi:10.1093/hmg/ddz008

32.   Benhammouda S, Vishwakarma A, Gatti P, Germain M. Mitochondria Endoplasmic Reticulum
Contact Sites (MERCs): Proximity Ligation Assay as a Tool to Study Organelle Interaction. *Front Cell*
Dev Biol. 2021;9:789959. doi:10.3389/fcell.2021.789959

33.   Züchner S, De Jonghe P, Jordanova A, et al. Axonal neuropathy with optic atrophy is caused by
mutations in mitofusin 2. *Ann Neurol*. 2006;59(2):276-281. doi:10.1002/ana.20797

34.   Rouzier C, Bannwarth S, Chaussenot A, et al. The MFN2 gene is responsible for mitochondrial
DNA instability and optic atrophy "plus" phenotype. *Brain*. 2012;135(Pt 1):23-34.
doi:10.1093/brain/awr323

35.   Pellino G, Faggioli R, Galuppi A, et al. Mitofusin 2: The missing link between mtDNA maintenance
defects and neurotransmitter disorders. *Mitochondrion*. 2021;61:159-164.
doi:10.1016/j.mito.2021.09.011

36.   Madrid R, Guariglia SR, Haworth A, Korosh W, Gavin M, Lyon GJ. Early-onset cerebellar ataxia in
a patient with CMT2A2. *Cold Spring Harb Mol Case Stud*. 2020;6(3):a005108.
doi:10.1101/mcs.a005108

37.   Eschenbacher WH, Song M, Chen Y, et al. Two rare human mitofusin 2 mutations alter
mitochondrial dynamics and induce retinal and cardiac pathology in Drosophila. *PLoS One*.
2012;7(9):e44296. doi:10.1371/journal.pone.0044296

38.   Vielhaber S, Debska-Vielhaber G, Peeva V, et al. Mitofusin 2 mutations affect mitochondrial
function by mitochondrial DNA depletion. *Acta Neuropathol*. 2013;125(2):245-256.
doi:10.1007/s00401-012-1036-y

39.   Loiseau D, Chevrollier A, Verny C, et al. Mitochondrial coupling defect in Charcot-Marie-Tooth
556   type 2A disease. *Ann Neurol*. 2007;61(4):315-323. doi:10.1002/ana.21086

557   40.   Luo N, Yue F, Jia Z, et al. Reduced electron transport chain complex I protein abundance and
558   function in Mfn2-deficient myogenic progenitors lead to oxidative stress and mitochondria swelling.
559   *FASEB J*. 2021;35(4):e21426. doi:10.1096/fj.202002464R

560   41.   Pagliarini DJ, Calvo SE, Chang B, et al. A mitochondrial protein compendium elucidates complex I
561   disease biology. *Cell*. 2008;134(1):112-123. doi:10.1016/j.cell.2008.06.016

562   42.   Hu C, Xu Q, Shen J, Wang Y. Clinical and Genetic Characteristics of Mitochondrial
563   Encephalopathy Due to FOXRED1 Mutations: Two Chinese Case Reports and a Review of the
564   Literature. *Front Neurol*. 2021;12:633397. doi:10.3389/fneur.2021.633397

565   43.   Calvo SE, Tucker EJ, Compton AG, et al. High-throughput, pooled sequencing identifies
566   mutations in NUBPL and FOXRED1 in human complex I deficiency. *Nat Genet*. 2010;42(10):851-858.
567   doi:10.1038/ng.659

568   44.   Zurita Rendón O, Antonicka H, Horvath R, Shoubridge EA. A Mutation in the Flavin Adenine
569   Dinucleotide-Dependent Oxidoreductase FOXRED1 Results in Cell-Type-Specific Assembly Defects in
570   Oxidative Phosphorylation Complexes I and II. *Mol Cell Biol*. 2016;36(16):2132-2140.
571   doi:10.1128/MCB.00066-16

572   45.   Haack TB, Madignier F, Herzer M, et al. Mutation screening of 75 candidate genes in 152
573   complex I deficiency cases identifies pathogenic variants in 16 genes including NDUFB9. *J Med Genet*.
574   2012;49(2):83-89. doi:10.1136/jmedgenet-2011-100577

575   46.   Marra F, Lunetti P, Curcio R, et al. An Overview of Mitochondrial Protein Defects in
576   Neuromuscular Diseases. *Biomolecules*. 2021;11(11):1633. doi:10.3390/biom11111633

577   47.   Chung CCY, Leung GKC, Mak CCY, et al. Rapid whole-exome sequencing facilitates precision
578   medicine in paediatric rare disease patients and reduces healthcare costs. *Lancet Reg Health West*
579   *Pac*. 2020;1:100001. doi:10.1016/j.lanwpc.2020.100001

580   48.   McDermott H, Sherlaw-Sturrock C, Baptista J, Hartles-Spencer L, Naik S. Rapid exome
581   sequencing in critically ill children impacts acute and long-term management of patients and their

582 families: A retrospective regional evaluation. *Eur J Med Genet*. 2022;65(9):104571.

583 doi:10.1016/j.ejmg.2022.104571

584 49. Freed AS, Clowes Candadai SV, Sikes MC, et al. The Impact of Rapid Exome Sequencing on

585 Medical Management of Critically Ill Children. *J Pediatr*. 2020;226:202-212.e1.

586 doi:10.1016/j.jpeds.2020.06.020

(A)

(B)

Figure 1

Figure 2

Control Fibroblasts

Nucleus | Mitochondria | dsDNA | 10 μm

MFN2 R334K

Nucleus | Mitochondria | dsDNA | 10 μm

B.

C.

D.

E.

kBP | CON VAR

48.5

Figure 3

Figure 4

Figure 5

Figure 6